Given the mechanistic overlap in cytokine signaling and barrier dysfunction across psoriasis, HS, and AD, Hsp90 inhibition may hold promise in AD, where conventional therapies often fall short in patients with severe, chronic, or treatment-resistant disease. The gene discussed is HSP90AB1; the disease is psoriasis.